Antiangiogenic tumor therapy

被引：10

作者：

Davis, DW ^{[1
]}

McConkey, DJ ^{[1
]}

Zhang, W ^{[1
]}

Herbst, RS ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA

来源：

BIOTECHNIQUES | 2003年 / 34卷 / 05期

关键词：

D O I：

10.2144/03345dd01

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：1048 / +

页数：9

共 99 条

[1] Temozolomide in combination with interferon α-2b in patients with metastatic melanoma -: A phase I dose-escalation study [J].

Agarwala, SS ;

Kirkwood, JM .

CANCER, 2003, 97 (01) :121-127

[2] Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 [J].

Albanell, J ;

Rojo, F ;

Baselga, J .

SEMINARS IN ONCOLOGY, 2001, 28 (05) :56-66

[3] Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition [J].

Albanell, J ;

Rojo, F ;

Averbuch, S ;

Feyereislova, A ;

Mascaro, JM ;

Herbst, R ;

LoRusso, P ;

Rischin, D ;

Sauleda, S ;

Gee, J ;

Nicholson, RI ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :110-124

[4] Phase II evaluation of thalidomide in patients with metastatic breast cancer [J].

Baidas, SM ;

Winer, EP ;

Fleming, GF ;

Harris, L ;

Pluda, JM ;

Crawford, JG ;

Yamauchi, H ;

Isaacs, C ;

Hanfelt, J ;

Tefft, M ;

Flockhart, D ;

Johnson, MD ;

Hawkins, MJ ;

Lippman, ME ;

Hayes, DF .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (14) :2710-2717

[5]

Baselga J, 1999, SEMIN ONCOL, V26, P78

[6] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[7] Neovastat (Æ-941) in refractory renal cell carcinoma patients:: report of a phase II trial with two dose levels [J].

Batist, G ;

Patenaude, F ;

Champagne, P ;

Croteau, D ;

Levinton, C ;

Hariton, C ;

Escudier, B ;

Dupont, E .

ANNALS OF ONCOLOGY, 2002, 13 (08) :1259-1263

[8] Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent [J].

Bernatchez, PN ;

Soker, S ;

Sirois, MG .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (43) :31047-31054

[9]

Bhargava P, 2001, CLIN CANCER RES, V7, P3912

[10]

BIER H, 1995, EUR ARCH OTO-RHINO-L, V252, P433

← 1 2 3 4 5 6 7 8 9 10 →